{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-08-13",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 10
    }
  },
  "results": [
    {
      "cfres_id": "148982",
      "product_res_number": "Z-0008-2017",
      "event_date_initiated": "2016-08-15",
      "event_date_posted": "2016-10-03",
      "recall_status": "Terminated",
      "event_date_terminated": "2017-01-04",
      "res_event_number": "74982",
      "product_code": "OUF",
      "k_numbers": [
        "K122766"
      ],
      "product_description": "Thermo Scientific QMS Everolimus Assay;\nModel number:\n0380000 (US Distribution);\n0373852 (Foreign Distribution)\n\nProduct Usage:\nThe QMS Everolimus Assay is intended for the quantitative determination of Everolimus, in human whole blood on automated clinical chemistry analyzers. The results obtained are used as an aid in the management of kidney and liver transplant patients receiving Everolimus therapy. This in vitro diagnostic device is intended for clinical laboratory use only. The QMS Everolimus assay is intended to be used as an aid in the management of patients receiving everolimus therapy for those organ transplant procedures indicated in the chart for each specific country.",
      "code_info": "Lot number: 72258049, Expiry date: 07/31/2017; Lot number: 72258007, Expiry date 07/31/2017.",
      "firm_fei_number": "3010939897",
      "recalling_firm": "Microgenics Corporation",
      "address_1": "46500 Kato Rd",
      "city": "Fremont",
      "state": "CA",
      "postal_code": "94538-7310",
      "additional_info_contact": "Jeffrey J/ Fisher\n510-979-5000",
      "reason_for_recall": "A reagent stability issue (still under investigation) causes less separation in the calibration curve, which affects results across the entire range.  For controls, maximum bias of +/- 35% for low levels, +/- 33% for mid-range levels, and +/- 47% for high levels is observed.  Bias in patient samples ranges from -15.7% to +5.2% with an average bias of -5.6% when comparing the QMS everolimus assay to an everolimus LC-MS reference method.  Patient samples across the measuring range  sub-therapeutic, therapeutic, and supra-therapeutic  could be affected.",
      "root_cause_description": "Under Investigation by firm",
      "action": "Thermo Fisher sent an Urgent Medical Device Field Action letter dated on August 15, 2016 to customers via regular mail. The letter identified the affected product, problem and actions to be taken.  Customers are advised to Discontinue use and destroy any remaining inventory of the affected lots per your local waste ordinances. Customers were instructed to cmplete the attached Medical Device Field Action Response Form and return the\nform to Thermo Fisher Scientific Technical Service.  For questions contact Technical Service at 1-800-232-3342 (USA only) or 510-979-5000 (outside the USA) then press option 2, then option 3.",
      "product_quantity": "163 kits in US, 669 kits worldwide - toatal 831.",
      "distribution_pattern": "Worldwide Distribution - US Nationwide in the states of KY, CA, NY, DC, NC, TX, IL, OH, IL, FL, IK, IA, MS and countries of Mexico, Taiwan, Guatemala, Malaysia, Argentina, Dominican Republic, Philippines, Germany, Australia.",
      "openfda": {
        "k_number": [
          "K122766",
          "K100144"
        ],
        "device_name": "Everolimus Immunoassay",
        "medical_specialty_description": "Clinical Toxicology",
        "regulation_number": "862.3840",
        "device_class": "2",
        "registration_number": [
          "2517506",
          "3010939897"
        ],
        "fei_number": [
          "2517506",
          "3010939897"
        ]
      }
    }
  ]
}